International Journal of Drug Policy
Volume 21, Issue 1 , Pages 36-42 , January 2010

Why don’t out-of-treatment individuals enter methadone treatment programmes?

Received 9 May 2008 ,Revised 16 July 2008 ,Accepted 30 July 2008.

References 

  1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed.. Washington, DC: APA Press; 1994;
  2. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcomes. New York: Springer-Verlag; 1991;
  3. Booth RE, Corsi KF, Mikulich SK. Improving entry to methadone maintenance among out-of-treatment injection drug users. Journal of Substance Abuse Treatment. 2003;24:305–311
  4. Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention and effectiveness: Out-of-treatment opiate injection users. Drug Alcohol Dependence. 1996;42:11–20
  5. Bourgois P. Disciplining addictions: The bio-politics of methadone and heroin in the United States. Culture, Medicines, and Psychiatry. 2000;24:165–195
  6. Brown BS. Treating the alcoholic: A developmental model of recovery. New York, NY: John Wiley and Sons; 1985;
  7. Brown BS, Hickey JE, Chung AS, Craig RD, Jaffe JH. The functioning of individuals on a drug abuse treatment waiting list. American Journal of Drug Alcohol Abuse. 1989;15(3):261–274
  8. Calsyn DA, DeMarco FJ, Saxon AJ, Sloan KL, Gibbon KE. Evaluation of a minimal services track for noncompliant patients in opioid substitution treatment. American Journal of Public Health. 2003;93(7):1086–1088
  9. Campbell KM, Deck D, Krupski A. Impact of substance abuse treatment on arrests among opiate users in Washington State. American Journal on Addiction. 2007;16(6):510–520
  10. Deck D, Carlson MJ. Retention in publicly funded methadone maintenance treatment in two western states. Journal of Behavioral Health Services Research. 2005;32(1):43–60
  11. Des Jarlais DC, Paone D, Friedman SR, Peyser N, Newman RG. Regulating controversial programs for unpopular people: Methadone maintenance and syringe exchange programs. American Journal of Public Health. 1995;85:1577–1584
  12. Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS. 1998;12(Suppl A):S217–S230
  13. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiatry Reports. 2007;9(5):358–364
  14. Friedman SR, Tempalski B, Perlis T, Keem M, Friedman R, Flom P. Estimating numbers of injecting drugs users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injection drug users. Journal of Urban Health. 2004;81:377–400
  15. Gilman SM, Galanter M, Dermatis H. Methadone anonymous: A 12-step program for methadone maintained heroin addicts. Substance Abuse. 2006;22(4):247–256
  16. Glasscote R, Sussex JN, Jaffe JH, Ball J, Brill L. The treatment of drug abuse: Programs, problems, prospects. Washington, DC: Joint Information Services. American Psychiatric Association; 1972;
  17. Glickman L, Galanter M, Dermatis H, Dingle S. Recovery and spiritual transformation among peer leaders of a modified methadone anonymous group. Journal of Psychoactive Drugs. 2006;38(4):531–533
  18. Goldsmith DS, Hunt DE, Lipton DS, Strug DL. Methadone folklore: beliefs about side effects and their impact on treatment. Human Organization. 1984;43:330–340
  19. Guggenbuhl L, Uchtenhagen A, Paris D. Adequacy in drug abuse treatment and care in Europe. Part II. Treatment and support needs of drug addicts. Zurich, Switzerland: Addiction Research Institute, A project of the World Health Organization; 2000;
  20. Guydish J, Woods WJ, Davis T, Bostrom A, Frazier Y. Does centralized intake improve drug abuse treatment outcomes. Journal Substance Abuse Treatment. 2001;20(4):265–273(275–276 discussion)
  21. Hanson B, Beschner G, Walters JW, Bovelle E. Life with heroin: Voices from the Inner City. Lexington, MA: Lexington Books; 1985;
  22. Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B. “It takes your heart”: The image of methadone maintenance in the addict world and its effect on recruitment into treatment. International Journal of the Addictions. 1985;20:1751–1771
  23. Jackson JF, Rotkiewicz G, Quinones MA, Passannante MR. A coupon program drug treatment and AIDS education. International Journal of the Addictions. 1989;24:1035–1051
  24. Krook AL, Brørs O, Dahlberg J, Grouff K, Magnus P, Røysamb E, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97(5):533–542
  25. Lewis DC. Access to narcotic treatment programs and medical care: Prospects for the expansion of methadone maintenance treatment. Journal of Addictive Disease. 1999;18:5–21
  26. Maddux JF, Prihoda TJ, Desmond DP. Treatment fees and retention on methadone maintenance. Journal of Drug Issues. 1994;24:429–443
  27. Magura S, Blankertz L, Madison EM, Friedman E, Gomez A. An innovative job placement model for unemployed methadone patients: A randomized clinical trial. Substance Use & Misuse. 2007;42(5):811–828
  28. Magura S, Rosenblum A, Lewis C, Joseph H. The effectiveness of in-jail methadone maintenance. Journal of Drug Issues. 1993;23:75–99
  29. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Dependence. 2001;61(2):195–206
  30. Mattick, R. P., Kimber, B. C., & Davoli, M. (2003). Methadone maintenance versus no opioid agonist replacement therapy for opioid dependence. The Cochrane data base of systematic reviews. Issue 2. Art. No. CD00209. DOI: 10.1002/14651858.CD0022209.
  31. McCarty D, Gustafson DH, Wisdom JP, Ford J, Choi D, Molfenter T, et al. The network for the improvement of addiction treatment: Enhancing access and retention. Drug and Alcohol Dependence. 2007;88(2/3):138–145
  32. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Reports. 1998;113(Suppl 1):97–106
  33. Metzger DS, Woody GE, McLellan AT, O’Brien CP, Druley P, Navaline H, et al. Human Immunodeficiency Virus Seroconversion among intravenous drug users in- and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes. 1993;6(9):1049–1056
  34. Moss AR, Varnizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco 1985–1990. AIDS. 1994;8:223–231
  35. Peterson J, Reisinger HS, Schwartz RP, Mitchell SG, Brown BS, Agar AH. Targeted sampling in drug abuse research: A review and case study. Field Methods. 2008;20(2):155–170
  36. Preble E, Casey JJ. Taking care of business: the heroin users’ life on the street. The International Journals of the Addictions. 1969;4(1):1–24
  37. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, et al. Attitudes and practices regarding the use of methadone in US state and federal prisons. Journal of Urban Health. 2005;82(3):411–419
  38. Riley ED, Safaeian M, Strathdee SA, Brooner RK, Beilenson P, Vlahov D. Drug user treatment referrals and entry among participants of a needle exchange program. Substance Use & Misuse. 2002;37(14):1869–1886
  39. Rosenblum A, Magura S, Joseph H. Ambivalence toward methadone treatment among intravenous drug users. Journal of Psychoactive Drugs. 1991;23:21–27
  40. Schwartz RP, Highfield DA, Jaffe JH, Brady JV, Butler CA, Rouse CO, et al. A randomized controlled trial of interim methadone maintenance. Archive of General Psychiatry. 2006;63:102–109
  41. Schwartz RP, Highfield DA, Jaffe JH, Callaman JM, O’Grady KE. A randomized controlled trial of interim methadone maintenance: 10 month-follow-up. Drug and Alcohol Dependence. 2007;86:30–36
  42. Schwartz RP, Kelly SM, O’Grady KE, Peterson JA, Reisinger HS, Mitchell SG, et al. In-treatment v. out-of-treatment opioid dependent adults: Drug use and criminal history. American Journal on Drug and Alcohol Abuse. 2008;34(1):17–28
  43. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. Journal on the American Medical Association. 2000;283(10):1303–1310
  44. Stancliff S, Myers JE, Steiner S, Drucker E. Beliefs about methadone in an Inner-City methadone Clinic Journal of Urban Health: Bulletin of the New York Academy of Medicine. The New York Academy of Medicine. 2002;79(4):
  45. Strauss A, Corbin J. Basics of qualitative research: Grounded theory procedures and techniques. Newbury Park, CA: Sage; 1991;
  46. Tomasino V, Swanson AJ, Nolan J, Shuman HI. The key extended entry program (KEEP): a methadone treatment program for opiate-dependent inmates. Mount Sinai Journal of Medicine. 2001;68:14–20
  47. Watters JK, Cheng Y. HIV-1 infection and risk among intravenous drug users in San Francisco: Preliminary results and implications. Contemporary Drug Problems. 1987;15:397–411
  48. Woody G, O’Hare K, Mintz J, O’Brien C. Rapid intake: A method for increasing retention rate of heroin addicts seeking methadone treatment. Comprehensive Psychiatry. 1975;16(2):165–169
  49. Woody GE, Muñoz A. Efficacy, individual effectiveness, and population effectiveness in substance abuse treatment. Current Psychiatry Reports. 2000;2(6):505–507
  50. Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedman P, Trigg HL, et al. A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health. 1991;81:1185–1191
  51. Zanis DA, Coviello D, Alterman AI, Appling SE. A community-based trial of vocational problem-solving to increase employment among methadone patients. Journal of Substance Abuse Treatment. 2001;21(1):19–26
  52. Zule WA, Desmond DP. Factors predicting entry of injecting drug users into substance abuse treatment. American Journal of Drug Alcohol Abuse. 2000;26(2):247–261
  53. Zule WA, Desmond DP. Attitudes toward methadone maintenance: Implications for HIV prevention. Journal of Psychoactive Drugs. 1998;30:89–97
  54. Zweben JE, Sorensen JL. Misunderstanding about methadone. Journal of Psychoactive Drugs. 1988;20(3):275–281

PII: S0955-3959(08)00169-2

doi: 10.1016/j.drugpo.2008.07.004

International Journal of Drug Policy
Volume 21, Issue 1 , Pages 36-42 , January 2010

Article Tools